Jul 21, 2017 Syros Publishes Foundational Data Supporting Ongoing Phase 2 Clinical Trial of SY-1425 for Genomically Defined AML and MDS Patients
Jun 23, 2017 Syros Presents Data at EHA Supporting Potential of SY-1425, Its First-in-Class Selective RARα Agonist, in Genomically Defined AML and MDS Patients
Jun 19, 2017 Syros Presents Discovery of Key Genes Controlling the Autoimmune Response in Lupus in Late-Breaking Oral Presentation at FOCIS Meeting
May 18, 2017 Syros to Present on SY-1425 in Combination with Standard-of-Care and Targeted Therapies in Genomically Defined Subsets of AML and MDS Patients
May 15, 2017 Syros Reports First Quarter 2017 Financial Results and Highlights Accomplishments and Upcoming Milestones
May 15, 2017 Syros Announces First Patient Dosed in Phase 1 Clinical Trial of SY-1365, Its First-in-Class Selective CDK7 Inhibitor, in Patients with Advanced Solid Tumors
May 8, 2017 Syros Announces Late-Breaking Oral Presentation on its Research Identifying Key Genes that Control the Auto-immune Response in Lupus at FOCIS Meeting
May 8, 2017 Syros Presents New Insights on Mechanism of Action of SY-1425, Its First-in-Class Selective RARα Agonist, in Oral Plenary Session at AACR Hematologic Malignancies Conference
